drugset / Trial / NCT02359474

Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin

NCT02359474

Phase 2 Unknown 120 enrolled Ludwig-Maximilians - University of Munich
RandomizedSingle-groupOpen-labelTreatment

Summary

This trial compares trabectedin alone to trabectedin in combination with regional hyperthermia in patients with high-risk soft tissue sarcoma. The study is designed to demonstrate a significant benefit for sarcoma-therapy by adding regional hyperthermia.

Timeline

Start
2014-12-19
Primary completion
2023-08
Completion
2023-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Trabectedin Small molecule 1.5 mg/m2 Intravenous

Indications